Incorporation of immunotherapies and nanomedicine to better normalize angiogenesis-based cancer treatment

Saade Abdalkareem Jasim; Irina M Farber; Sara Abdalrazzaq M Noraldeen; Pooja Bansal; Hashem O Alsaab; Bekhzod Abdullaev; Adnan Taan Alkhafaji; Ahmed Hussien Alawadi; Hamza Fadhel Hamzah; Bahira Abdulrazzaq Mohammed

doi:10.1016/j.mvr.2024.104691

Incorporation of immunotherapies and nanomedicine to better normalize angiogenesis-based cancer treatment

Microvasc Res. 2024 Jul:154:104691. doi: 10.1016/j.mvr.2024.104691. Epub 2024 May 3.

Affiliations

¹ Medical Laboratory Techniques Department, Al-Maarif University College, Anbar, Iraq.
² Department of children's diseases of the F. Filatov clinical institute of children's health, I. M. Sechenov First Moscow State Medical University of Health of Russian Federation (Sechenov University), Moscow, Russia.
³ Department of Oncology and Metabolism, University of Tabuk, Tabuk, Saudi Arabia.
⁴ Department of Biotechnology and Genetics, Jain (Deemed-to-be) University, Bengaluru, Karnataka 560069, India; Department of Allied Healthcare and Sciences, Vivekananda Global University, Jaipur, Rajasthan 303012, India.
⁵ Department of Pharmaceutics and Pharmaceutical Technology, Taif University, Taif 21944, Saudi Arabia.
⁶ Research Department of Biotechnology, New Uzbekistan University, Mustaqillik Avenue 54, Tashkent 100007, Uzbekistan; Department of Oncology, School of Medicine, Central Asian University, Milliy Bog Street 264, Tashkent 111221, Uzbekistan.. Electronic address: ayntraxt@gmail.com.
⁷ Cardiology Department, College of Medicine, Al-Ayen University, Thi-Qar, Iraq.
⁸ College of Technical Engineering, the Islamic University, Najaf, Iraq; College of Technical Engineering, the Islamic University of Al Diwaniyah, Qadisiyyah, Iraq; College of Technical Engineering, the Islamic University of Babylon, Babylon, Iraq.
⁹ Department of Medical Laboratories Technology, AL-Nisour University College, Baghdad, Iraq.
¹⁰ Department of Technical Engineering, Al-Hadi University College, Baghdad 10011, Iraq.

PMID: 38703993
DOI: 10.1016/j.mvr.2024.104691

Abstract

Neoadjuvant targeting of tumor angiogenesis has been developed and approved for the treatment of malignant tumors. However, vascular disruption leads to tumor hypoxia, which exacerbates the treatment process and causes drug resistance. In addition, successful delivery of therapeutic agents and efficacy of radiotherapy require normal vascular networks and sufficient oxygen, which complete tumor vasculopathy hinders their efficacy. In view of this controversy, an optimal dose of FDA-approved anti-angiogenic agents and combination with other therapies, such as immunotherapy and the use of nanocarrier-mediated targeted therapy, could improve therapeutic regimens, reduce the need for administration of high doses of chemotherapeutic agents and subsequently reduce side effects. Here, we review the mechanism of anti-angiogenic agents, highlight the challenges of existing therapies, and present how the combination of immunotherapies and nanomedicine could improve angiogenesis-based tumor treatment.

Trial registration: ClinicalTrials.gov NCT00479674.

Keywords: Angiogenesis; Combination therapy; Drug resistance; Hypoxic tumor; Targeted therapy; Tumor vasculature.

Publication types

Review

MeSH terms

Angiogenesis
Angiogenesis Inhibitors*
Animals
Antineoplastic Agents, Immunological / administration & dosage
Antineoplastic Agents, Immunological / therapeutic use
Humans
Immunotherapy*
Nanomedicine
Neoplasms* / blood supply
Neoplasms* / drug therapy
Neoplasms* / immunology
Neoplasms* / therapy
Neovascularization, Pathologic*
Tumor Microenvironment

Substances

Angiogenesis Inhibitors
Antineoplastic Agents, Immunological

Associated data

ClinicalTrials.gov/NCT00479674